Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis
Recruiting
18-99 years
All
Phase
3
175 participants needed
1 Location
Brief description of study
The primary purpose of this study is to evaluate the safety and efficacy of ravulizumab for the treatment of participants with generalized myasthenia gravis (gMG).
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Myasthenia Gravis
-
Age: Between 18 Years - 99 Years
-
Gender: All
Male and Female, Age 18 or older, Diagnosis of Myasthenia Gravis
Updated on
01 Aug 2024.
Study ID: 834121
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
A copy of the message has been sent to your email
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
